PAREXEL International Corporation (PRXL) Releases Earnings Results, Reports EPS of $0.89 EPS

PAREXEL International Corporation (PRXL) reported quarterly earnings results on Wednesday, Apr-27-2016. The company reported $0.89 EPS for the quarter. Analysts had a consensus estimate of $0.89. The company posted revenue of $527.10 million in the period, compared to analysts expectations of $523.31 million. The company’s revenue was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.66 EPS.

Many Wall Street Analysts have commented on PAREXEL International Corporation. PAREXEL International Corporation was Upgraded by Sun Trust Rbsn Humphrey to ” Buy” on Mar 28, 2016.

PAREXEL International Corporation opened for trading at $66.66 and hit $67.75 on the upside on Friday, eventually ending the session at $67.64, with a gain of 1.23% or 0.82 points. The heightened volatility saw the trading volume jump to 4,28,219 shares. Company has a market cap of $3,632 M.

In a different news, on Mar 3, 2016, Christopher J Lindop (director) sold 2,000 shares at $60.28 per share price. According to the SEC, on Dec 2, 2015, Richard L Love (director) sold 1,330 shares at $68.21 per share price. On Nov 24, 2015, Eduard E. Holdener (director) sold 2,200 shares at $67.66 per share price, according to the Form-4 filing with the securities and exchange commission.

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company which provides a range of expertise in clinical research clinical logistics medical communications consulting commercialization and advanced technology products and services to the pharmaceutical biotechnology and medical device industries across the world. The Company operates through three segments: Clinical Research Services PAREXEL Consulting Services and PAREXEL Informatics. Its product and service offerings include clinical trials management data management epidemiology health economics/outcomes research pharmacovigilance medical communications clinical pharmacology patient recruitment clinical supply and drug logistics post-marketing surveillance medical imaging services electronic data capture systems clinical trial management systems Web-based portals and other product development tools and services.

PAREXEL International Corporation

Leave a Reply

PAREXEL International Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on PAREXEL International Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.